English

Landos Biopharma, Inc.

EDGAR

LABP Quarterly report (10-Q) · filed 2024-05-09

18 filing records in this dataset, filed from 2021-01-13 to 2024-05-09. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Cash and cash equivalents: 29 million USD 2024-03-31 Source
Exact value

29004000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 3.12 million shares 2024-03-31 Source
Exact value

3116729 shares

Reported share-count change

-90.00% · -28.1 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

31168449 shares · 2023-03-31· Source
3116729 shares · 2024-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-24.8 million USD

2023-04-01 – 2024-03-31

Exact inputs and evidence

Net income: -3922000 USD · 2023-04-01 – 2023-06-30 Source
Net income: -5860000 USD · 2023-07-01 – 2023-09-30 Source
Net income: -21935000 USD · 2023-01-01 – 2023-12-31 Source
Net income: -15816000 USD · 2023-01-01 – 2023-09-30 Source
Net income: -8897000 USD · 2024-01-01 – 2024-03-31 Source

Operating cash flow

-20.8 million USD

2023-04-01 – 2024-03-31

Exact inputs and evidence

Operating cash flow: -13280000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -8170000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -15508000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -13280000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -20477000 USD · 2023-01-01 – 2023-12-31 Source
Operating cash flow: -15508000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -8498000 USD · 2024-01-01 – 2024-03-31 Source

Capital expenditure

0 USD

2023-01-01 – 2023-12-31

Exact inputs and evidence

Capital expenditure: 0 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 0 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 0 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 0 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 0 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 0 USD · 2023-01-01 – 2023-12-31 Source
Capital expenditure: 0 USD · 2023-01-01 – 2023-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-05-09.

Financial data available through: 2023-12-31.

Coverage by financial measure

revenue: No compatible figures in this window
Operating income: 4 of 11 periods available· newest 2023-12-31
Net income: 4 of 11 periods available· newest 2023-12-31
Operating cash flow: 4 of 11 periods available· newest 2023-12-31
Capital expenditure: 4 of 11 periods available· newest 2023-12-31
Total assets: 4 of 11 periods available· newest 2023-12-31
Total liabilities: 4 of 11 periods available· newest 2023-12-31
Current assets: 4 of 11 periods available· newest 2023-12-31
Current liabilities: 4 of 11 periods available· newest 2023-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2023-12-31
long term debt: No compatible figures in this window
Shares outstanding: 4 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 17.34 million

Prior period

−USD 39.28 million

2022-01-01 – 2022-12-31
Current period

−USD 21.94 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-21935000 − -39276000 = 17341000 USD

-39276000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-21935000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Landos Biopharma, Inc. · 2023-12-31 Landos Biopharma, Inc. (edgar:1785345) Year-over-year change in Net income: 17341000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -21935000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017024034438/labp-20231231.htm#1346387 Filing: 000095017024034438 Input fundies:NetIncome: -39276000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017024034438/labp-20231231.htm#1347834 Filing: 000095017024034438
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 25.29 million

Prior period

−USD 45.77 million

2022-01-01 – 2022-12-31
Current period

−USD 20.48 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-20477000 − -45771000 = 25294000 USD

-45771000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-20477000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Landos Biopharma, Inc. · 2023-12-31 Landos Biopharma, Inc. (edgar:1785345) Year-over-year change in Operating cash flow: 25294000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -20477000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017024034438/labp-20231231.htm#1225227 Filing: 000095017024034438 Input fundies:OperatingCashFlow: -45771000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017024034438/labp-20231231.htm#1226670 Filing: 000095017024034438
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-100%

Prior period

USD 7,000

2022-01-01 – 2022-12-31
Current period

USD 0

2023-01-01 – 2023-12-31

Exact inputs and evidence

0 − 7000 = -7000 USD

7000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
0 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Landos Biopharma, Inc. · 2023-12-31 Landos Biopharma, Inc. (edgar:1785345) Year-over-year change in Capital expenditure: -7000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017024034438/labp-20231231.htm#1230099 Filing: 000095017024034438 Input fundies:CapitalExpenditure: 7000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017024034438/labp-20231231.htm#1231382 Filing: 000095017024034438
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.

Values and sources

Revenue values and source evidence
Period	Series	Value	Source evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value	Source evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 30.14 million Exact value Exact value: -30144000 USD 2020-01-01 – 2020-12-31: -30144000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Landos Biopharma, Inc. · 2020-12-31 Landos Biopharma, Inc. (edgar:1785345) Net Income: -30144000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -30144000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017022004559/labp-20211231.htm#1446049 Filing: 000095017022004559 The citation records this snapshot. The page link may show a newer release later.	−USD 22.96 million Exact value Exact value: -22962000 USD 2020-01-01 – 2020-12-31: -22962000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Landos Biopharma, Inc. · 2020-12-31 Landos Biopharma, Inc. (edgar:1785345) Operating Cash Flow: -22962000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22962000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017022004559/labp-20211231.htm#1619875 Filing: 000095017022004559 The citation records this snapshot. The page link may show a newer release later.	USD 181,000 Exact value Exact value: 181000 USD 2020-01-01 – 2020-12-31: 181000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Landos Biopharma, Inc. · 2020-12-31 Landos Biopharma, Inc. (edgar:1785345) Capital Expenditure: 181000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 181000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017022004559/labp-20211231.htm#1627028 Filing: 000095017022004559 The citation records this snapshot. The page link may show a newer release later.	−USD 23.14 million Calculation and evidence -22962000 − 181000 USD Exact free cash flow: -23143000 USD 2020-01-01 – 2020-12-31: -22962000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 181000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Landos Biopharma, Inc. · 2020-12-31 Landos Biopharma, Inc. (edgar:1785345) Free cash flow: -23143000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22962000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017022004559/labp-20211231.htm#1619875 Filing: 000095017022004559 Input fundies:CapitalExpenditure: 181000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017022004559/labp-20211231.htm#1627028 Filing: 000095017022004559 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 38.42 million Exact value Exact value: -38422000 USD 2021-01-01 – 2021-12-31: -38422000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Landos Biopharma, Inc. · 2021-12-31 Landos Biopharma, Inc. (edgar:1785345) Net Income: -38422000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38422000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017023009334/labp-20221231.htm#1518799 Filing: 000095017023009334 The citation records this snapshot. The page link may show a newer release later.	−USD 27.06 million Exact value Exact value: -27061000 USD 2021-01-01 – 2021-12-31: -27061000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Landos Biopharma, Inc. · 2021-12-31 Landos Biopharma, Inc. (edgar:1785345) Operating Cash Flow: -27061000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -27061000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017023009334/labp-20221231.htm#1680382 Filing: 000095017023009334 The citation records this snapshot. The page link may show a newer release later.	USD 440,000 Exact value Exact value: 440000 USD 2021-01-01 – 2021-12-31: 440000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Landos Biopharma, Inc. · 2021-12-31 Landos Biopharma, Inc. (edgar:1785345) Capital Expenditure: 440000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 440000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017023009334/labp-20221231.htm#1688321 Filing: 000095017023009334 The citation records this snapshot. The page link may show a newer release later.	−USD 27.5 million Calculation and evidence -27061000 − 440000 USD Exact free cash flow: -27501000 USD 2021-01-01 – 2021-12-31: -27061000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 440000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Landos Biopharma, Inc. · 2021-12-31 Landos Biopharma, Inc. (edgar:1785345) Free cash flow: -27501000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -27061000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017023009334/labp-20221231.htm#1680382 Filing: 000095017023009334 Input fundies:CapitalExpenditure: 440000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017023009334/labp-20221231.htm#1688321 Filing: 000095017023009334 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 39.28 million Exact value Exact value: -39276000 USD 2022-01-01 – 2022-12-31: -39276000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Landos Biopharma, Inc. · 2022-12-31 Landos Biopharma, Inc. (edgar:1785345) Net Income: -39276000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -39276000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017024034438/labp-20231231.htm#1347834 Filing: 000095017024034438 The citation records this snapshot. The page link may show a newer release later.	−USD 45.77 million Exact value Exact value: -45771000 USD 2022-01-01 – 2022-12-31: -45771000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Landos Biopharma, Inc. · 2022-12-31 Landos Biopharma, Inc. (edgar:1785345) Operating Cash Flow: -45771000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -45771000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017024034438/labp-20231231.htm#1226670 Filing: 000095017024034438 The citation records this snapshot. The page link may show a newer release later.	USD 7,000 Exact value Exact value: 7000 USD 2022-01-01 – 2022-12-31: 7000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Landos Biopharma, Inc. · 2022-12-31 Landos Biopharma, Inc. (edgar:1785345) Capital Expenditure: 7000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017024034438/labp-20231231.htm#1231382 Filing: 000095017024034438 The citation records this snapshot. The page link may show a newer release later.	−USD 45.78 million Calculation and evidence -45771000 − 7000 USD Exact free cash flow: -45778000 USD 2022-01-01 – 2022-12-31: -45771000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 7000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Landos Biopharma, Inc. · 2022-12-31 Landos Biopharma, Inc. (edgar:1785345) Free cash flow: -45778000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -45771000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017024034438/labp-20231231.htm#1226670 Filing: 000095017024034438 Input fundies:CapitalExpenditure: 7000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017024034438/labp-20231231.htm#1231382 Filing: 000095017024034438 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 21.94 million Exact value Exact value: -21935000 USD 2023-01-01 – 2023-12-31: -21935000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Landos Biopharma, Inc. · 2023-12-31 Landos Biopharma, Inc. (edgar:1785345) Net Income: -21935000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -21935000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017024034438/labp-20231231.htm#1346387 Filing: 000095017024034438 The citation records this snapshot. The page link may show a newer release later.	−USD 20.48 million Exact value Exact value: -20477000 USD 2023-01-01 – 2023-12-31: -20477000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Landos Biopharma, Inc. · 2023-12-31 Landos Biopharma, Inc. (edgar:1785345) Operating Cash Flow: -20477000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -20477000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017024034438/labp-20231231.htm#1225227 Filing: 000095017024034438 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2023-01-01 – 2023-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Landos Biopharma, Inc. · 2023-12-31 Landos Biopharma, Inc. (edgar:1785345) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017024034438/labp-20231231.htm#1230099 Filing: 000095017024034438 The citation records this snapshot. The page link may show a newer release later.	−USD 20.48 million Calculation and evidence -20477000 − 0 USD Exact free cash flow: -20477000 USD 2023-01-01 – 2023-12-31: -20477000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Landos Biopharma, Inc. · 2023-12-31 Landos Biopharma, Inc. (edgar:1785345) Free cash flow: -20477000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:47:15Z Snapshot: 9d0200b53e978d12715361cbdd57098270ba2352acbb158e353e2872feebe7ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785345?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -20477000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017024034438/labp-20231231.htm#1225227 Filing: 000095017024034438 Input fundies:CapitalExpenditure: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785345/000095017024034438/labp-20231231.htm#1230099 Filing: 000095017024034438 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

18 filings · 890 latest values · 890 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001785345, 1785345, LABP, edgar:1785345

Also known as Landos Biopharma, Inc.

Landos Biopharma, Inc.

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

Growth

Profit and cash

Balance sheet

Cash generation